Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 14,479

Document Document Title
WO/2019/141096A1
Provided is a substituted urea compound, and a preparation method and use thereof. More particularly, the invention relates to a substituted urea compound or a pharmaceutically acceptable salt, a stereoisomer, a polymorphic substance, a ...  
WO/2019/143677A1
Compounds, methods of editing a target genomic region(s), methods of repairing of a DNA break via a HDR pathway, methods of inhibiting or suppressing repair of a DNA break via a NHEJ pathway, and methods of modifying expression of a gene...  
WO/2019/141179A1
The present invention relates to the field of medical chemistry, and relates to a novel pyridone derivative represented by formula (I) or a stereoisomer thereof, a pharmaceutically acceptable salt, a solvate or a crystal thereof, and an ...  
WO/2019/143718A1
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions,...  
WO/2019/129025A1
The present invention discloses a tetrahydropyrrole compound, a preparation method therefor, a pharmaceutical composition containing the same, and a use thereof. The tetrahydropyrrole compound of the present invention is represented by g...  
WO/2019/131798A1
Provided is a cell growth inhibitor containing, as an active ingredient, a compound represented by general formula (1) below, or a pharmacologically acceptable salt thereof. [In general formula (1), J1 and J2 represent CH or N, but both ...  
WO/2019/128963A1
Disclosed is a substituted nitroimidazole derivative, in particular, disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a pharmaceutical composition comprising the abov...  
WO/2019/121843A1
The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.  
WO/2019/119141A1
The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and...  
WO/2019/126731A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described ...  
WO/2019/126622A1
Provided herein are isoxazole compounds, pharmaceutical compositions thereof, methods of preparing such compounds and compositions, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.  
WO/2019/119207A1
Provided are compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.  
WO/2019/120213A1
The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as...  
WO/2019/120267A1
Disclosed is an imidazo[1,2-b]pyridazine macrocyclic kinase inhibitor. The compound or a stereoisomer, or a crystal form, or a pharmaceutically acceptable salt, or a solvate, or a prodrug, or a metabolite thereof is as shown in formula (...  
WO/2019/126730A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are d...  
WO/2019/111218A1
The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatmen...  
WO/2019/110751A1
The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them an...  
WO/2019/109188A1
The present application is directed to compounds of Formula (I)-(VI): (I), (II), (III), (IV), (V) (VI), (VII) and (VIII), compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.  
WO/2019/110413A1
The present invention relates to the improved synthesis of noroxymorphone of formula (III). Particularly, the invention shows a way how to reduce the impurity level in the product avoiding lengthy purification steps.  
WO/2019/110006A1
Disclosed are a compound represented by the general formula (I), or a stereisomer, a tautomer, a derivative, a prodrug or a pharmaceutically acceptable salt thereof, and a method for preparing the compound and the use of the compound in ...  
WO/2019/110613A1
The present invention relates to a novel process for the synthesis of herbicidal pyrazolidinedione compounds. In particular, a process for the preparation of a compound of formula (I), wherein R1, R2 and R3 are as defined herein. The pre...  
WO/2019/108591A1
The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof (1) wherein each of R1, R2, R3, R4, L1, and L2, are as defined herein. The present invention also contempl...  
WO/2018/125880A8
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.  
WO/2019/106693A1
The compounds of Formula I and Formula (B) are described herein along with their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms, and pharma...  
WO/2019/103060A1
The present invention addresses the problem of providing a drug to be used to prevent or treat obesity or to prevent or treat type 2 diabetes. The means for solution according to the present invention is a compound represented by general...  
WO/2019/102494A1
The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabo...  
WO/2019/096914A1
The present invention relates to macrocyclic indole derivatives of general formula (I) : in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing sai...  
WO/2019/096905A1
The present invention relates to macrocyclic indole derivatives of general formula (I) : (I), in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparin...  
WO/2019/097479A1
PAT057954-WO-PCT ABSTRACT The invention provides compounds of Formula (I) n R3b Z W Q R3a H Y N R1 R4 R2 O (I) as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositi...  
WO/2018/227058A9
The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPRl) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...  
WO/2019/096909A1
The present invention relates to macrocyclic indole derivatives of general formula (I) : in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing sai...  
WO/2019/096907A1
The present invention relates to aryl annulated macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for...  
WO/2019/098259A1
The present invention provides a preparation which remains substantially uncolored even when irradiated with light, by coating a preparation containing the compound represented by formula (I), a salt of said compound, or a crystal of the...  
WO/2019/096922A1
The present invention relates to substituted macrocyclic indole derivatives of general formula (I) in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for pre...  
WO/2019/096241A1
Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I).  
WO/2019/086469A1
The present invention relates to a novel route of synthesis for the production of enantiomerically pure Cobimetinib, new intermediates in the synthesis of Cobimetinib and an amorphous Cobimetinib hemifumarate salt comprising a high salt ...  
WO/2019/089335A1
Compounds of Formula I, pharmaceutically acceptable salts thereof, tautomers thereof, pharmaceutically acceptable salts of the tautomers, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular an...  
WO/2019/090198A1
Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activi...  
WO/2019/089580A1
The present invention provides methods of treating hematological disorders and solid malignant tumors, using substituted indazole compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and BCL-2 kinases.  
WO/2019/089422A1
Compounds of Formula I as IRAK4 inhibitors are disclosed. The pharmaceutical compositions comprising compounds of formula I, methods of synthesis of these compounds, methods of treatment for diseases associated with IRAK-4 such as inflam...  
WO/2019/082910A1
Provided are: a V2 receptor antagonist which has high water solubility and which is particularly suitable for injections; and a medicine containing the V2 receptor antagonist or the like. The present invention is a compound represented b...  
WO/2019/080878A1
This disclosure relates to heterocyclics as selective inhibitors of the fibroblast growth factor receptor 4 (FGFR-4), in particular relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical ...  
WO/2019/082808A1
This pest control agent contains, as an active ingredient, a compound represented by formula (I) or a salt thereof, and at least one selected from the group consisting of the compound and a salt thereof. In formula (I), Ar represents a p...  
WO/2019/084497A1
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by...  
WO/2019/081485A1
The invention relates to substituted pyrazoles of general formula (I) or salts thereof, wherein the groups of general formula (I) are defined as cited in the description, and to the use thereof as herbicides, in particular for controllin...  
WO/2019/081477A1
The invention relates to substituted pyrazoles of general formula (I) or salts thereof, wherein the groups of general formula (I) are defined as cited in the description, and to the use thereof as herbicides, in particular for controllin...  
WO/2019/080941A1
This invention relates to certain novel tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors, their synthesis and their use for treating diseases. More particularly, this invention is directed to fused heterocyclic deri...  
WO/2019/081559A1
A compound of formula (I): in which A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and the use thereof in the production of medicaments.  
WO/2019/079357A1
TNIK inhibitors, conjugates thereof, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in treating of cancer by modulating T...  
WO/2017/223280A3
The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.  

Matches 301 - 350 out of 14,479